merck p53 stapled peptide stapled peptide-based radiotheranostic agents - new-england-peptide stapled Merck p53 Stapled Peptide: A Promising Frontier in Cancer Therapy

six-peptide-eye-cream The field of oncology is continuously evolving, with researchers exploring innovative therapeutic strategies to combat cancer. One such area of intense investigation revolves around the p53 protein, a critical tumor suppressor, and its interaction with negative regulators like MDM2 and MDMXCell-Permeable Peptide Inhibitors of the p53-hDM2 .... This interaction, a protein-protein interaction (PPI), is frequently dysregulated in various cancers, leading to the uncontrolled proliferation of malignant cells. Emerging from this research is a novel class of therapeutic agents known as stapled peptides, which are showing significant promise in reactivating the tumor-suppressing functions of p53. Specifically, the development of a Merck p53 stapled peptide represents a significant advancement in this therapeutic arena.

Understanding the p53-MDM2 Interaction and the Rationale for Stapled Peptides

The p53 protein acts as a guardian of the genome, initiating cell cycle arrest, apoptosis, or senescence in response to DNA damage or cellular stress. However, MDM2 acts as an E3 ubiquitin ligase, targeting p53 for degradation, thereby limiting its tumor-suppressive activity. In many cancers, MDM2 is overexpressed, leading to excessive p53 degradation and contributing to tumor development.2023年7月27日—This drug candidate ismeant to mimic a key helix in the p53 protein, famous as a regulatory system in oncology, and to thus bind to its MDM2 ... Similarly, MDMX (also known as MDM4) can inhibit p53 function through a different mechanism.作者：MH Reutershan·2021·被引用次数：26—Design-rules forstapled peptides with in vivo activityand their application to Mdm2/X antagonists. Nature Communications 2024, 15 (1) ...

The interaction between p53 and MDM2 (and MDMX) occurs through specific helical regions. Traditional small molecules have struggled to effectively disrupt these PPIs due to their complexity and the need for high affinity and specificity.作者：YS Chang·2013·被引用次数：812—We report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates thep53pathway in tumors in vitro and in vivo. This is where stapled peptides come into playOptimal Stapling of a Helical Peptide‐Foldamer Hybrid .... These are modified peptides designed to mimic the helical structure of p53 that binds to MDM2Novel Stapled Peptide P53 Therapy Enhances Anti .... The "stapling" involves introducing covalent cross-links, often hydrocarbon linkers, between amino acid residues. This modification enhances the peptide's α-helicity, conformational stability, and resistance to enzymatic degradation, making them more drug-like and capable of penetrating cells.

The Development of Merck p53 Stapled Peptide Candidates

Merck, a leading pharmaceutical company, has been actively involved in the research and development of stapled peptides targeting the p53 pathway. While specific internal project names may not be publicly disclosed, the general concept of a Merck p53 stapled peptide refers to their efforts in this domain.作者：K Ingelshed—We found that thep53activatingstapled peptideMDM2/MDMX inhibitor Sulanemadlin (ALRN-6924) inhibitedp53wild-type cancer cell growth in ... These efforts are rooted in the understanding that stapled peptides can effectively prevent MDM2 from suppressing wild-type p53.

Several research initiatives highlight the potential of stapled peptides in this context. For instance, the stapled peptide PM2 has demonstrated its ability to stabilize p53 levels by preventing MDM2-mediated degradation, positioning it as a promising agent for therapeutic combinationsDesign-Rules for Stapled Alpha-Helical Peptides with On- .... Another notable compound, Sulanemadlin (ALRN-6924), is a p53-activating stapled peptide that acts as an MDM2/MDMX inhibitor. This cell-penetrating stapled alpha-helical peptide is designed to equipotently disrupt the interaction between the p53 tumor suppressor protein and its inhibitors. Preliminary results have shown promising responses, including durable complete responses in some patients作者：S Baek·2012·被引用次数：325—We present here a 2.0 Å resolution structure of the Mdm2 protein with a boundstapled p53 peptide. Suchpeptides, which are conformationally and ....

The development process for these stapled peptides involves meticulous design and optimization.作者：G Tiwari·2016—In order to inhibit the p53-MDM2 interaction, we have successfully designedstapled peptides(sMTide-02)1, 2. It is a potential lead compound for drug ... Researchers focus on creating peptides that are not only potent inhibitors of the p53-MDM2 PPI but also possess favorable pharmacokinetic properties, such as in vivo activity. Workflows for identifying stapled peptides against MDM2(X) with in vivo activity and no off-target effects are crucial for their successful translation into clinical useStapled α−helical peptide drug development: A potent dual .... The goal is to develop peptides that are meant to mimic a key helix in the p53 protein, thereby restoring its tumor-suppressive functions.

Variations and Innovations in Stapled Peptide Design

The innovation in stapled peptide technology extends beyond simple hydrocarbon stapling. Researchers are exploring various approaches to enhance their efficacy and therapeutic utility:

* Bicyclic Stapled Peptides: Compounds like bicyclic stapled peptide p53-16 have shown significantly improved α-helicity and proteolytic stability, leading to nanomolar binding affinities to target proteinsOptimal Stapling of a Helical Peptide‐Foldamer Hybrid Using ....

* Dual Inhibitors: Some stapled peptides are designed as potent dual inhibitors of MDM2 and MDMX, such as ATSP-7041, which effectively activate the p53 pathway in tumors.

* Stereoisomerism: The study of stereoisomerism of stapled peptide inhibitors of the p53 interaction is important for understanding how staple geometry influences biological activity.

* Foldamer Hybrids: Integrating stapled peptide motifs with foldamers can lead to novel structures like the i,i+7 stapled peptide-foldamer which exhibits high-affinity binding to hDM2 and restores the p53 signaling pathwayFunctionalized Double Strain-Promoted Stapled Peptides ....

* Radiotheranostics: Stapled peptide-based radiotheranostic agents are being developed for PET-imaging guided radiotherapy of p53 mutant cancerOptimal Stapling of a Helical Peptide‐Foldamer Hybrid Using .... For instance, [64Cu]Cu-DOTA-STP has shown efficacy in inhibiting tumor growth, regardless of p53 phenotypes.

* PROTACs: Design of stapled peptide-based PROTACs for MDM2/MDMX degradation is another area of active research, aiming to enhance targeted protein degradation.Cell-Permeable Peptide Inhibitors of the p53-hDM2 ...

* Alternative Linkers: Exploration of linear aliphatic dialkynes as alternative linkers for double stapling has led to potent p53 peptides like Stapled peptide SP6.

These advancements underscore the versatility and potential of stapled peptides as a therapeutic modality作者：G Tiwari·2016—In order to inhibit the p53-MDM2 interaction, we have successfully designedstapled peptides(sMTide-02)1, 2. It is a potential lead compound for drug .... The ability of stapled peptides to shapeshift to slip through cellular barriers and target key disease-related proteins within cells makes them a compelling strategy for developing anti-cancer therapeutic leads.

The Future of Merck p53 Stapled Peptides in Oncology

The research into Merck p53 stapled peptides and related compounds signifies a promising direction in cancer treatment. By effectively reactivating the p53 pathway and inhibiting the oncogenic functions of MDM2 and MDMX, these peptides have exhibited great potential as anti-cancer drugs作者：TY Yuen·2019·被引用次数：35—In this study, we evaluated the effect of staple geometry on the biological activity of fivep53-reactivatingpeptides.. The ongoing clinical trials and preclinical investigations are crucial for validating their safety and efficacy in patients. As our understanding of PPI inhibition deepens and stapled peptide technology continues to mature, these innovative agents are poised to play a significant role in the future of cancer therapy, offering new hope for patients battling various forms of the disease. The journey from laboratory discovery to clinical application is complex, but the progress made with stapled peptides in targeting the p53 pathway is a testament to scientific ingenuity and perseverance.